Combination Therapy In Dyslipidemia
Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evalua...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Cham :
Springer International Publishing : Imprint: Adis,
2015.
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Foreword
- Statins and bile acid resins – is there a place for such a combination?
- Statins and fibrates – should it be recommended?
- Statins and ezetimibe – doubts or bright future?
- Statins and niacin – the end of residual risk therapy?
- Statins and omega-3 fatty acids – what more do we need?
- Statins and CETP inhibitors – anacetrapib and evacetrapib – the last hope?
- Statins and mipomersen – the issue of tolerability?
- Statins and lomitapide – a suitable response for HoFH
- Statins and PCSK9 inhibitors – defining the correct patients
- Other possible drug combination for dyslipidaemia
- Statins and nutraceuticals/functional food – Could be they combined?
- Lipid lowering therapy and apheresis – indications and outcomes
- Combination of lipid lowering agents with antihypertensive drugs – a joint fight against the two most important risk factors?
- Not only dyslipidaemia therapy – the time for polypills
- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom?
- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance?
- Conclusions and Take Home Message.
